Burcu Ceren Uludoğan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Burcu Ceren Uludoğan has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Reşit Yıldırım
The Royal Wolverhampton NHS Trust, Wolverhampton, UK
8 shared publications - Cengiz Korkmaz
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye
6 shared publications - Döndü Üsküdar Cansu
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye
6 shared publications - Nazife Şule Yaşar Bilge
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey
6 shared publications - Timuçin Kaşifoğlu
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey
5 shared publications - Cemal Bes
Department of Rheumatology, University of Health Sciences, Başakşehir Çam and Sakura City Hospital , Istanbul
4 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
The effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study
- 24 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessThe effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study
- Open Access
- 16 June 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (3) , 730-739
Non-pulmonary arterial involvement in Behçet's disease: a multicentre retrospective case series
Background/aim: In Behçet’s disease (BD), arterial involvement represents a significant clinical challenge associated with serious complications. The present study evaluates the characteristic features, affected vessels, lesion types, treatments, and outcomes in BD patients with nonpulmonary arterial involvement. Materials and methods: Included in this retrospective study were 65 BD patients whose interventions and clinical courses were accessed from medical records. The treatments administered included immunosuppressive (IS) therapies and surgical/endovascular procedures. Fisher’s exact and t-test/Mann–Whitney U test were used for statistical analysis. Results: Fifty-nine of the patients (90.8%) were male. The median (Q1–Q3) follow-up was 4 (2–12.8) years. The most commonly affected vessels were the aorta (n = 21, 32.3%) and the femoral artery (n = 19, 29.2%). Aneurysm (n = 50, 63.2%) and thrombosis (n = 18, 22.7%) were the predominant lesions; 14 (21.5%) patients experienced arterial involvement while receiving IS therapy; and 11 (16.9%) had cardiac involvement. Cyclophosphamide and azathioprine were the most commonly used IS agents. Among the 39 (60%) patients who underwent surgical and/or interventional procedures, 32 (82%) had successful outcomes. A second arterial event was experienced by 15.3% of the sample during follow-up, and a third by 3%. Active disease was noted in nine (13.8%) patients at the time of their last visit, and of the six (9.2%) that died, most had both arterial and cardiac involvement. Conclusion: Arterial involvement in BD mostly presents with aneurysms, especially in men. Surgical interventions in addition to IS therapies are required in approximately 50% of cases. As can be understood from the 15.3% relapse rate in the present study, arterial events are not uncommon, underlining the need for long-term monitoring and sustained IS treatment. Of the 9.2% of cases who died, most had both arterial and cardiac involvement.
- 16 June 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (3) , 730-739
Open AccessNon-pulmonary arterial involvement in Behçet's disease: a multicentre retrospective case series
Background/aim: In Behçet’s disease (BD), arterial involvement represents a significant clinical challenge associated with serious complications. The present study evaluates the characteristic features, affected vessels, lesion types, treatments, and outcomes in BD patients with nonpulmonary arterial involvement. Materials and methods: Included in this retrospective study were 65 BD patients whose interventions and clinical courses were accessed from medical records. The treatments administered included immunosuppressive (IS) therapies and surgical/endovascular procedures. Fisher’s exact and t-test/Mann–Whitney U test were used for statistical analysis. Results: Fifty-nine of the patients (90.8%) were male. The median (Q1–Q3) follow-up was 4 (2–12.8) years. The most commonly affected vessels were the aorta (n = 21, 32.3%) and the femoral artery (n = 19, 29.2%). Aneurysm (n = 50, 63.2%) and thrombosis (n = 18, 22.7%) were the predominant lesions; 14 (21.5%) patients experienced arterial involvement while receiving IS therapy; and 11 (16.9%) had cardiac involvement. Cyclophosphamide and azathioprine were the most commonly used IS agents. Among the 39 (60%) patients who underwent surgical and/or interventional procedures, 32 (82%) had successful outcomes. A second arterial event was experienced by 15.3% of the sample during follow-up, and a third by 3%. Active disease was noted in nine (13.8%) patients at the time of their last visit, and of the six (9.2%) that died, most had both arterial and cardiac involvement. Conclusion: Arterial involvement in BD mostly presents with aneurysms, especially in men. Surgical interventions in addition to IS therapies are required in approximately 50% of cases. As can be understood from the 15.3% relapse rate in the present study, arterial events are not uncommon, underlining the need for long-term monitoring and sustained IS treatment. Of the 9.2% of cases who died, most had both arterial and cardiac involvement.
- Open Access
- 28 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
Frequency and associated factors of hepatic hemangioma in systemic lupus erythematosus patients undergoing abdominal imaging: a retrospective cohort study
Hepatic hemangioma may be detected in patients with systemic lupus erythematosus (SLE). This study aimed to determine the frequency, radiological characteristics, and potential associated factors of hepatic hemangioma in SLE patients undergoing abdominal imaging. We retrospectively evaluated 221 of 402 SLE patients followed at a tertiary university hospital who underwent abdominal imaging for clinical indications. Demographic, clinical, laboratory, and radiological data were collected from medical records. Factors associated with hepatic hemangioma were analyzed. A total of 221 SLE patients who underwent abdominal imaging were included. All patients underwent abdominal ultrasound as the primary imaging modality. The mean age was 49.62 ± 13.75 years, 86.4% were female, mean age at SLE diagnosis was 36.29 ± 14.48 years, and mean disease duration was 12.81 ± 8.14 years. The most common indication for abdominal imaging was asymptomatic/routine screening/pre-renal biopsy evaluation (n = 117, 53%). Hepatic hemangioma was detected in 11.8% (n = 26) of the imaged SLE patients. Among these, 69.2% were identified after SLE diagnosis, 27% concurrently, and 3.8% before diagnosis. Most hemangiomas were solitary (65.4%), with a mean diameter of 2.57 ± 2.22 cm. Patients with hepatic hemangioma had significantly longer disease duration (15.85 ± 7.82 vs. 12.40 ± 8.12 years; p = 0.043) and follow-up duration (15.38 ± 7.98 vs. 11.61 ± 7.89 years; p = 0.030) compared to those without. At SLE diagnosis, pleuritis (19.2% vs. 5.6%; p = 0.035), autoimmune hemolytic anemia (AIHA) (38.5% vs. 18.6%; p = 0.037), and C3 hypocomplementemia (80.8% vs. 55.4%; p = 0.014) were significantly more common in the hemangioma group. Multivariate logistic regression analysis revealed that longer SLE disease duration (OR 1.06 per year; 95% CI 1.01–1.12; p = 0.020) and presence of AIHA at diagnosis (OR 3.42; 95% CI 1.32–8.88; p = 0.011) were independently associated with hepatic hemangioma. Hepatic hemangiomas may be incidentally detected in SLE patients undergoing abdominal imaging. They were significantly more frequent in patients with longer disease duration and in those with AIHA at SLE diagnosis. However, these findings should be interpreted cautiously due to the retrospective design and selected nature of the study population. Prospective longitudinal studies with unselected SLE cohorts and appropriate control groups are needed to better define the true frequency and their associated factors of hepatic hemangiomas in SLE.
- 28 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6)
Open AccessFrequency and associated factors of hepatic hemangioma in systemic lupus erythematosus patients undergoing abdominal imaging: a retrospective cohort study
Hepatic hemangioma may be detected in patients with systemic lupus erythematosus (SLE). This study aimed to determine the frequency, radiological characteristics, and potential associated factors of hepatic hemangioma in SLE patients undergoing abdominal imaging. We retrospectively evaluated 221 of 402 SLE patients followed at a tertiary university hospital who underwent abdominal imaging for clinical indications. Demographic, clinical, laboratory, and radiological data were collected from medical records. Factors associated with hepatic hemangioma were analyzed. A total of 221 SLE patients who underwent abdominal imaging were included. All patients underwent abdominal ultrasound as the primary imaging modality. The mean age was 49.62 ± 13.75 years, 86.4% were female, mean age at SLE diagnosis was 36.29 ± 14.48 years, and mean disease duration was 12.81 ± 8.14 years. The most common indication for abdominal imaging was asymptomatic/routine screening/pre-renal biopsy evaluation (n = 117, 53%). Hepatic hemangioma was detected in 11.8% (n = 26) of the imaged SLE patients. Among these, 69.2% were identified after SLE diagnosis, 27% concurrently, and 3.8% before diagnosis. Most hemangiomas were solitary (65.4%), with a mean diameter of 2.57 ± 2.22 cm. Patients with hepatic hemangioma had significantly longer disease duration (15.85 ± 7.82 vs. 12.40 ± 8.12 years; p = 0.043) and follow-up duration (15.38 ± 7.98 vs. 11.61 ± 7.89 years; p = 0.030) compared to those without. At SLE diagnosis, pleuritis (19.2% vs. 5.6%; p = 0.035), autoimmune hemolytic anemia (AIHA) (38.5% vs. 18.6%; p = 0.037), and C3 hypocomplementemia (80.8% vs. 55.4%; p = 0.014) were significantly more common in the hemangioma group. Multivariate logistic regression analysis revealed that longer SLE disease duration (OR 1.06 per year; 95% CI 1.01–1.12; p = 0.020) and presence of AIHA at diagnosis (OR 3.42; 95% CI 1.32–8.88; p = 0.011) were independently associated with hepatic hemangioma. Hepatic hemangiomas may be incidentally detected in SLE patients undergoing abdominal imaging. They were significantly more frequent in patients with longer disease duration and in those with AIHA at SLE diagnosis. However, these findings should be interpreted cautiously due to the retrospective design and selected nature of the study population. Prospective longitudinal studies with unselected SLE cohorts and appropriate control groups are needed to better define the true frequency and their associated factors of hepatic hemangiomas in SLE.
- Open Access
- 31 March 2026
- Published by Medical Center "Edem Medical" LLC in Anti-Aging Eastern Europe
- Vol. 5 (1) , 47-53
LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL FEATURES, COMORBIDITIES, AND MORTALITY IN A SINGLE-CENTER COHORT
Background: Late-onset systemic lupus erythematosus (Lo-SLE) is a rare subgroup of SLE characterized by disease onset at ≥50 years of age and a distinct clinical phenotype. This study aims to evaluate the clinical and laboratory characteristics, comorbidities, and mortality rates of Lo-SLE patients treated at our center. Materials and Methods: This single-center retrospective study included Lo-SLE patients diagnosed with SLE at our center between 2010 and 2025 and whose disease onset age was ≥50 years. The patients’ demographic characteristics, clinical findings, organ involvement, laboratory data, and treatments administered were obtained from medical records. Additionally, comorbidities, mortality rates, and causes of death were analysed. Results: The mean age at SLE diagnosis for the 39 Lo-SLE patients included in the study was 57.8±6.5 years, and 82.1% of the patients were female. The most common clinical findings were hematological abnormalities; renal involvement was detected at a relatively lower frequency. One patient was diagnosed with transverse myelitis. The positivity rates for anti-nuclear antibody (ANA) and anti-dsDNA were 100% and 82.1%, respectively. During a mean follow-up period of 8.2±6.8 years, the most common comorbidity was hypertension (46.2%), and malignancy developed in 4 (10.3%) patients. All patients used hydroxychloroquine during follow-up, while 79.5% of patients received steroids and 59% received at least one immunosuppressive treatment. The mortality rate in the cohort was 35.9%, with the most common causes of death being cardiovascular diseases and infections. Conclusion: Our single-center experience shows that hematological involvement, such as autoimmune hemolytic anemia and immune thrombocytopenia, is more common in Lo-SLE patients, but that a diagnosis can also be made with neurological findings, such as transverse myelitis, in rare cases. It should be kept in mind that malignancies, as well as comorbidities such as hypertension, may be seen in the Lo-SLE group, and cardiovascular diseases and infections are important causes of mortality.
- 31 March 2026
- Published by Medical Center "Edem Medical" LLC in Anti-Aging Eastern Europe
- Vol. 5 (1) , 47-53
Open AccessLATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL FEATURES, COMORBIDITIES, AND MORTALITY IN A SINGLE-CENTER COHORT
Background: Late-onset systemic lupus erythematosus (Lo-SLE) is a rare subgroup of SLE characterized by disease onset at ≥50 years of age and a distinct clinical phenotype. This study aims to evaluate the clinical and laboratory characteristics, comorbidities, and mortality rates of Lo-SLE patients treated at our center. Materials and Methods: This single-center retrospective study included Lo-SLE patients diagnosed with SLE at our center between 2010 and 2025 and whose disease onset age was ≥50 years. The patients’ demographic characteristics, clinical findings, organ involvement, laboratory data, and treatments administered were obtained from medical records. Additionally, comorbidities, mortality rates, and causes of death were analysed. Results: The mean age at SLE diagnosis for the 39 Lo-SLE patients included in the study was 57.8±6.5 years, and 82.1% of the patients were female. The most common clinical findings were hematological abnormalities; renal involvement was detected at a relatively lower frequency. One patient was diagnosed with transverse myelitis. The positivity rates for anti-nuclear antibody (ANA) and anti-dsDNA were 100% and 82.1%, respectively. During a mean follow-up period of 8.2±6.8 years, the most common comorbidity was hypertension (46.2%), and malignancy developed in 4 (10.3%) patients. All patients used hydroxychloroquine during follow-up, while 79.5% of patients received steroids and 59% received at least one immunosuppressive treatment. The mortality rate in the cohort was 35.9%, with the most common causes of death being cardiovascular diseases and infections. Conclusion: Our single-center experience shows that hematological involvement, such as autoimmune hemolytic anemia and immune thrombocytopenia, is more common in Lo-SLE patients, but that a diagnosis can also be made with neurological findings, such as transverse myelitis, in rare cases. It should be kept in mind that malignancies, as well as comorbidities such as hypertension, may be seen in the Lo-SLE group, and cardiovascular diseases and infections are important causes of mortality.
- 29 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Clinical significance of non-infectious procalcitonin elevation in Still’s disease: a predictor of macrophage activation syndrome
Objectives: Still’s disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. Methods: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. Results: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. Conclusion: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.
- 29 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Clinical significance of non-infectious procalcitonin elevation in Still’s disease: a predictor of macrophage activation syndrome
Objectives: Still’s disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. Methods: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. Results: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. Conclusion: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 997-1002
İnflamatuvar Miyopatilerde Miyozit Spesifik Antikorlar ve Klinik Kullanımı: Tek Merkez Deneyimi
Miyozit spesifik antikorlar (MSA), inflamatuvar miyozitleri sınıflandırmada, klinik seyir ve prognozu öngörmede son yıllarda artan sıklıkla kullanılmaktadır. Bu çalışmada merkezimizde takipli inflamatuvar miyopatili hastalar içerisinde miyozit spesifik antikoru çalışılmış hastaların demografik özellikleri, tanıları, klinik bulguları, laboratuvar verileri, antikor profilleri, enfeksiyöz komplikasyon ve malignite gelişimi ve mortalite verileri analiz edildi. Çalışmaya toplam 33 hasta dahil edildi (29 kadın, 4 erkek). Medyan yaş 52 yıl (15-72) ve medyan takip süresi 27 ay (2-250) olarak hesaplandı. Hastaların 15 (%45.4)’i dermatomiyozit tanılı idi. Hastaların 26’sında MSA pozitif saptandı. En sık pozitif saptanan antikorlar Jo-1 (%26,9) ve TIF-1 gamma (%23,1) idi. MSA pozitif inflamatuvar myopatili hastalarda konstitüsyonel semptomlar daha sık görülmekteydi (p:0,011). MSA alt gruplarına (Jo-1 ve diğerleri/ TIF-1 gamma ve diğerleri/ MDA-5 ve diğerleri) göre klinik bulgular değerlendirildiğinde; pulmoner tutulum ile Jo-1 pozitifliği (p<0,001) ve MDA-5 pozitifliği ile kalsinozis (p:0,018) arasında istatistiksel olarak anlamlı bir ilişki bulundu. Toplam 13 hastada infeksiyöz komplikasyonlar ve 3 hastada malignite gelişmişti (serviks, over ve kolorektal karsinom). Çalışmamızda MSA alt gruplarının sıklığı literatür ile benzerlik taşısa da genelleme yapabilmek için geniş hasta popülasyonunda yapılacak çalışmalara ihtiyaç vardır.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 997-1002
İnflamatuvar Miyopatilerde Miyozit Spesifik Antikorlar ve Klinik Kullanımı: Tek Merkez Deneyimi
Miyozit spesifik antikorlar (MSA), inflamatuvar miyozitleri sınıflandırmada, klinik seyir ve prognozu öngörmede son yıllarda artan sıklıkla kullanılmaktadır. Bu çalışmada merkezimizde takipli inflamatuvar miyopatili hastalar içerisinde miyozit spesifik antikoru çalışılmış hastaların demografik özellikleri, tanıları, klinik bulguları, laboratuvar verileri, antikor profilleri, enfeksiyöz komplikasyon ve malignite gelişimi ve mortalite verileri analiz edildi. Çalışmaya toplam 33 hasta dahil edildi (29 kadın, 4 erkek). Medyan yaş 52 yıl (15-72) ve medyan takip süresi 27 ay (2-250) olarak hesaplandı. Hastaların 15 (%45.4)’i dermatomiyozit tanılı idi. Hastaların 26’sında MSA pozitif saptandı. En sık pozitif saptanan antikorlar Jo-1 (%26,9) ve TIF-1 gamma (%23,1) idi. MSA pozitif inflamatuvar myopatili hastalarda konstitüsyonel semptomlar daha sık görülmekteydi (p:0,011). MSA alt gruplarına (Jo-1 ve diğerleri/ TIF-1 gamma ve diğerleri/ MDA-5 ve diğerleri) göre klinik bulgular değerlendirildiğinde; pulmoner tutulum ile Jo-1 pozitifliği (p<0,001) ve MDA-5 pozitifliği ile kalsinozis (p:0,018) arasında istatistiksel olarak anlamlı bir ilişki bulundu. Toplam 13 hastada infeksiyöz komplikasyonlar ve 3 hastada malignite gelişmişti (serviks, over ve kolorektal karsinom). Çalışmamızda MSA alt gruplarının sıklığı literatür ile benzerlik taşısa da genelleme yapabilmek için geniş hasta popülasyonunda yapılacak çalışmalara ihtiyaç vardır.
- Open Access
- 7 July 2025
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 12 (2) , 1-5
Clinical Features and Phenotypic Similarities of Patients with Familial Behçet’s Disease
Background: Behçet’s disease (BD) exhibits significant phenotypic diversity. The genetic basis of phenotypic variations in BD has not yet been elucidated. Based on the high frequency of familial BD, we aimed to analyze the familial aggregation of various manifestations of BD in this study. Methods: Patients with BD from 3 Turkish tertiary rheumatology outpatient clinics were evaluated. Demographic and clinical characteristics of the familial group with either a first- or second-degree relative with BD and the non-familial group were compared. Afterward, patients in the familial disease group for 5 years or longer were divided into 2: an “index patient” and a “first-degree relative patient” and the presence of BD manifestations were compared between these 2 groups. Results: We identified 864 BD patients (mean age (SD): 47.9 (12) years, disease duration (SD): 83.7 (65.3) months) with 251 (29.1%) having a BD family history. Genital ulcers (P =.002) and papulopustular lesions (P < .001) were detected more frequently in the familial group. Also in the familial group, statistically significant correlations were detected between the index patient and the first-degree relativepatient in terms of erythema nodosum-like lesions (r: 0.398, P: .016), pathergy test positivity (r: 0.561, P: .002), peripheral joint involvement (r: 0.563, P < .001) and vascular involvement (r: 0.408, P: .014). Conclusion: Familial BD may differ from sporadic BD. Additionally, erythema nodosum-like lesions, pathergy test positivity, and vascular and joint involvement may tend to show familial aggregation. Cite this article as: Abacar K, Elif Boncukcuoğlu A, Deniz R, et al. Clinical features and phenotypic similarities of patients with familial Behçet’s disease. Eur J Rheumatol. 2025, 12(2), 0116, doi: 10.5152/eurjrheum.2025.24116.
- 7 July 2025
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 12 (2) , 1-5
Open AccessClinical Features and Phenotypic Similarities of Patients with Familial Behçet’s Disease
Background: Behçet’s disease (BD) exhibits significant phenotypic diversity. The genetic basis of phenotypic variations in BD has not yet been elucidated. Based on the high frequency of familial BD, we aimed to analyze the familial aggregation of various manifestations of BD in this study. Methods: Patients with BD from 3 Turkish tertiary rheumatology outpatient clinics were evaluated. Demographic and clinical characteristics of the familial group with either a first- or second-degree relative with BD and the non-familial group were compared. Afterward, patients in the familial disease group for 5 years or longer were divided into 2: an “index patient” and a “first-degree relative patient” and the presence of BD manifestations were compared between these 2 groups. Results: We identified 864 BD patients (mean age (SD): 47.9 (12) years, disease duration (SD): 83.7 (65.3) months) with 251 (29.1%) having a BD family history. Genital ulcers (P =.002) and papulopustular lesions (P < .001) were detected more frequently in the familial group. Also in the familial group, statistically significant correlations were detected between the index patient and the first-degree relativepatient in terms of erythema nodosum-like lesions (r: 0.398, P: .016), pathergy test positivity (r: 0.561, P: .002), peripheral joint involvement (r: 0.563, P < .001) and vascular involvement (r: 0.408, P: .014). Conclusion: Familial BD may differ from sporadic BD. Additionally, erythema nodosum-like lesions, pathergy test positivity, and vascular and joint involvement may tend to show familial aggregation. Cite this article as: Abacar K, Elif Boncukcuoğlu A, Deniz R, et al. Clinical features and phenotypic similarities of patients with familial Behçet’s disease. Eur J Rheumatol. 2025, 12(2), 0116, doi: 10.5152/eurjrheum.2025.24116.
- Open Access
- 29 April 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (2) , 81-86
Are Male Patients with Behçet’s Disease Unlucky? : An Analysis of 506 Behçet Patients
Background Behçet's Disease (BD) is characterized by oral and genital ulcers, arthritis, skin manifestations, uveitis, gastrointestinal tract, and central nervous system involvement. Although it is known to be more severe in men, there are studies in the literature with conflicting results regarding gender and the distribution of clinical findings. This study aimed to examine the relationship between clinical findings and gender in BD patients and to compare our results with the literature. Methods 506 patients diagnosed with Behçet's disease were included in the study. Demographic data, laboratory, and clinical findings of the patients were obtained retrospectively from hospital records. The distribution of clinical findings according to gender was evaluated. Results A total of 280 males (55.3%) and 226 females (44.7%) were included in the study. There was no significant difference between male and female patients regarding age at diagnosis (p=0.662). Genital ulcer (47.6% vs 52.4%, p=0.011), superficial thrombophlebitis (20.9% vs 79.1%, p=0.002), uveitis (33.7% vs 66.3%, p=0.02), deep vein thrombosis (22.5% vs 77.5%, p=0.00) and pulmonary artery aneurysm (11.1% vs 88.9%, p=0.046) were more common in males. There was no significant difference between the sexes in other clinical findings, HLA B5, and pathergy positivity. Conclusion Gender impacts the clinical manifestations of BD and should be considered in patient follow-up. However, it is a heterogeneous disease, other factors may certainly affect the emergence of clinical findings.
- 29 April 2025
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 7 (2) , 81-86
Open AccessAre Male Patients with Behçet’s Disease Unlucky? : An Analysis of 506 Behçet Patients
Background Behçet's Disease (BD) is characterized by oral and genital ulcers, arthritis, skin manifestations, uveitis, gastrointestinal tract, and central nervous system involvement. Although it is known to be more severe in men, there are studies in the literature with conflicting results regarding gender and the distribution of clinical findings. This study aimed to examine the relationship between clinical findings and gender in BD patients and to compare our results with the literature. Methods 506 patients diagnosed with Behçet's disease were included in the study. Demographic data, laboratory, and clinical findings of the patients were obtained retrospectively from hospital records. The distribution of clinical findings according to gender was evaluated. Results A total of 280 males (55.3%) and 226 females (44.7%) were included in the study. There was no significant difference between male and female patients regarding age at diagnosis (p=0.662). Genital ulcer (47.6% vs 52.4%, p=0.011), superficial thrombophlebitis (20.9% vs 79.1%, p=0.002), uveitis (33.7% vs 66.3%, p=0.02), deep vein thrombosis (22.5% vs 77.5%, p=0.00) and pulmonary artery aneurysm (11.1% vs 88.9%, p=0.046) were more common in males. There was no significant difference between the sexes in other clinical findings, HLA B5, and pathergy positivity. Conclusion Gender impacts the clinical manifestations of BD and should be considered in patient follow-up. However, it is a heterogeneous disease, other factors may certainly affect the emergence of clinical findings.
- 8 July 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (7) , e15250
Rare involvement in Behcet's disease at once: Bilateral axillary artery aneurysms and microaneurysms in the gastrointestinal vasculature
- 8 July 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (7) , e15250
Rare involvement in Behcet's disease at once: Bilateral axillary artery aneurysms and microaneurysms in the gastrointestinal vasculature